中药临床研究联合用药安全性评价的思考和建议

doi:10.19803/j.1672-8629.2021.01.02

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (1): 4-10.
DOI: 10.19803/j.1672-8629.2021.01.02

• 复方与联合用药安全性评价专栏(第一辑) • 上一篇下一篇

中药临床研究联合用药安全性评价的思考和建议

程金莲¹, 欧阳绘天², 靳洪涛³, 朱雪琦¹, 肖爽¹, 雷翔², 高春升², 刘清泉^1,*

¹首都医科大学附属北京中医医院,北京 100010;
²北京岐黄药品临床研究中心,北京 100058;
³中国医学科学院北京协和医学院药物研究所新药安全评价研究中心,北京 100050

收稿日期:2020-09-16 修回日期:2021-01-18 出版日期:2021-01-15 发布日期:2021-01-18
通讯作者: ^*刘清泉,男,本科,主任医师,教授,中西医结合防治突发传染病、脓毒症、耐药菌感染等急危重症研究。
作者简介:程金莲,女,硕士,主任医师,中药临床药理与中医针灸。
基金资助:
国家“十三五”重大新药创制专项(2019ZX09734001)

Thoughts and Suggestions on Safety Evaluation of Combined use of Traditional Chinese Medicine in Clinical Research

CHENG Jinlian¹, OUYANG Huitian², JIN Hongtao³, ZHU Xueqi¹, XIAO Shuang¹, LEI Xiang², GAO Chunsheng², LIU Qingquan^1,*

¹Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing 100010,China;
²Beijing Qihuang Clinical Research Center,Beijing 100058,China;
³New Drug Safety Evaluation Center,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China

Received:2020-09-16 Revised:2021-01-18 Online:2021-01-15 Published:2021-01-18

摘要/Abstract

摘要： 目的探讨中药临床研究联合用药安全性评价方法,以满足临床安全、有效用药的需求。方法从中药临床研究入手,分析中药临床研究联合用药安全性存在的问题,并对其关键问题提出适当的建议。结果中药联合用药安全性评价体系需要建设和完善。结论中药联合用药的安全性评价需要从研发早期开始,贯穿临床试验至上市后评价的药品全生命周期;重视研究设计和风险-获益评估,搭建研究设计-监测评价-分析预测-风险管理的动态研究模式,建立多学科的综合评估体系。

关键词: 中药, 临床研究, 联合用药, 药物相互作用, 安全性评价

Abstract: Objective To study methods for safety evaluation of combined use of traditional Chinese medicine in clinical research in order to meet the needs of clinically safe and effective medication.Methods Starting with the clinical study of Traditional Chinese medicine,this paper analyzes the problems with the safety of combined use of traditional Chinese medicine in clinical study,and offers solutions to the major problems.Results A safety evaluation system for drug combination of TCM and Western medicine needed to be established and improved.Conclusion The safety evaluation of drug combination of TCM and Western medicine should start with the early stage of development and run through the life cycle of new drugs from clinical trial to post-marketing evaluation.Importance should be attached to research design and risk-benefit assessment.A dynamic research model of research design-monitoring evaluation-analysis prediction-risk management is to be adopted,and a multidisciplinary comprehensive assessment system established.

Key words: traditional Chinese medicine(TCM), clinical research, drug combination, drug-drug interaction(DDI), safety evaluation

中图分类号:

R288R969.3

程金莲, 欧阳绘天, 靳洪涛, 朱雪琦, 肖爽, 雷翔, 高春升, 刘清泉. 中药临床研究联合用药安全性评价的思考和建议[J]. 中国药物警戒, 2021, 18(1): 4-10.

CHENG Jinlian, OUYANG Huitian, JIN Hongtao, ZHU Xueqi, XIAO Shuang, LEI Xiang, GAO Chunsheng, LIU Qingquan. Thoughts and Suggestions on Safety Evaluation of Combined use of Traditional Chinese Medicine in Clinical Research[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 4-10.

参考文献

[1] Li H,Shen KK.Research progress of drug combination of Chinese materia medica on antitumor[J],Academic Journal of Shanghai University of Traditional Chinese Medicine(上海中医药大学学报),2017,31(3):90-94.
[2] Zheng CX,Zheng XY,Kong LX,et al.Potential medication risk analysis of Chinese patent medicine in the treatment of stable chronic obstructive pulmonary disease[J].China Pharmacy(中国药房),2020,31(7):841-844.
[3] Yang XB,Li XH,Wang F,et al.Research progress of traditional Chinese medicine intervention in septic shock[J].Yunnan Journal of Traditional Chinese Medicine and Materia Medica(云南中医中药杂志),2019,40(7):68-70.
[4] Hong F,Teng L,He JC.Research progress of interaction between Chinese medicine and western medicine in treatment of chronic heart failure[J].Chinese Journal of Cardiovascular Rehabilitation Medicine(心血管康复医学杂志),2020,29(2):253-255.
[5] Poonam T,Prakash GP,Kumar LV.Influence of Allium sativum extract on the hypoglycemic activity of glibenclamide:an approach to possible herb-drug interaction[J].Drug Metabol Drug Interact,2013,28(4):225-30.
[6] Fu H,Rong YH,Wang L.Rationality evaluation of traditional Chinese medicine injections for promoting blood circulation in patients with cerebral infarction in Jiangsu Province Hospital of Chinese Medicine from 2017 to 2018[J].Drugs &Clinic(现代药物与临床) ,2020,35(1):154-159.
[7] Zhuang W,Sun N,Wang J,et al.Role and experience of clinical pharmacist in the combination of warfarin and traditional Chinese medicine[J].China Pharmacist(中药临床药学),2019,22(6):1072-1075,1087.
[8] Jiang YN.Clinical analysis of 160 patients with drug-induced liver injury[J].Medical Journal of Chinese People's Health(中国民康医学),2019,31(22):111-112.
[9] Singh A,Zhao K,Bell C,et al.Effect of berberine on in vitro metabolism of sulfonylureas:A herb-drug interactions study[J].Rapid Communications in Mass Spectrometry,2019,34(S4):e8651.
[10] Li H,Yang C,Jin H.Recent research progress in mechanism of liver injury induced by common drugs[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(12):750-756.
[11] National Center for ADR Monitoring,China.2019 Annual report for national ADR monitoring[EB/OL].(2020-04-10)[2020-09-09].http://www.cdr-adr.org.cn/drug_1/aqjs_1/drug_aqjs_sjbg/202004/t20200420_47318.html.
[12] Huang T.Analysis of adverse drug reactions of 387 cases induced by Traditional Chinese Medicine Injections in Kunshan city[J].Journal of Modern Medicine &Health(现代医药卫生),2019,35(11):1643-1646.
[13] National Administration of Traditional Chinese Medicine.Guiding principles for clinical application of Chinese patent medicine[EB/OL].(2010-06-30)[2020-09-09].http://www.satcm.gov.cn/yizhengsi/gongzuodongtai/2018-03-24/3071.html.
[14] Brown AC.Liver toxicity related to herbs and dietary supplements:Online table of case reports Part 2 of 5 series[J].Food Chem Toxicol,2017,107(Pt A):472-501.
[15] Shuting Wang,Wanfang Li,Jianbo Yang,et al.Research progress of herbal medicines on drug metabolizing enzymes:consideration based on toxicology[J].Current Drug Metabolism ,2020,21:1-15.
[16] Hao JX,Zhang HD,Xiong KP,et al.Randomized controlled clinical trial of felodipine tablets combined used with tianmagouteng granules on treating hypertension[J/OL].Journal of Practical Traditional Chinese Internal Medicine(实用中医内科杂志).http://kns.cnki.net/kcms/detail/21.1187.r.20200310.1940.031.html.
[17] Liu QL,Gong QJ,Yu XY.Application of traditional Chinese medicine in drug application of traditional Chinese medicine in drug combination for coronary heart disease[J].Technology and Enterprise(科技与企业) ,2014(8):286-287.
[18] Guo JY,Huo HR,Jiang TL.Evaluation of research methods to measure the effects of combined drugs[J].Pharmacology and Clinics of Chinese Materia Medica(中药药理与临床),2005,21(3):60-64.
[19] ICH.M3(R2) Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals[EB/OL].(2009-06-11)[2020-09-09].https://database.ich.org/sites/default/files/M3_R2__Guideline.pdf.
[20] Center for drug evaluation,NMPA of China.Technical guidelines for drug interaction research (exposure draft)[EB/OL].(2020-09-11)[2020-09-25].http://www.cde.org.cn/news.do?method=largeInfo&id=a24d50a14e59b266.
[21] Center for drug evaluation,NMPA of China.Technical guidelines for clinical trials of combination therapy with antitumor agents(exposure draft)[EB/OL].(2020-07-17)[2020-09-09].http://www.cde.org.cn/news.do?method=largeInfo&id=5d938422a5c1c7e6.
[22] Zhu XQ,Cheng JL,Liu QQ.Thoughts on the registration of new traditional Chinese medicines in the COVID-19 epidemic situation[J].Chinese Journal of New Drugs (中国新药杂志),2020,29(16):1813-1817.
[23] Lu S.Introduction of guidance for clinical evsluation of an ti-rheumatic drugs in Japan[J].Chin J Clin Pharmacol(中国临床药理学杂志) ,2010,26(8):634-640.
[24] Dong H,Ma J,Li T,et al.Global deregulation of ginseng products may be a safety hazard to warfarin takers:solid evidence of ginseng-warfarin interaction[J].Scientific Reports,2017,7(1):5813
[25] Mohutsky MA,Anderson GD,Miller JW,et al.Ginkgo biloba:evaluation of CYP2C9 drug interactions in vitro and in vivo[J].AmJ Ther,2006,13(1):24-31.
[26] Matthews MK,Jr,Association of Ginkgo biloba with intracerebral hemorrhage[J],Neurology,1998,50(6) 1933-1934.
[27] Tian Z,Pang H,Du S,et al.Effect of Panax notoginseng saponins on the pharmacokinetics of aspirin in rats[J].J Chromatogr B Analyt Technol Biomed Life Sci,2017,1040:136-143.
[28] Zhou L,Wang S,Zhang Z,et al.Pharmacokinetic and pharmaco-dynamic interaction of Danshen-Gegen extract with warfarin and aspirin[J].J Ethnopharmacol,2012,143(2):648-55.
[29] Chen X,Jin J,Chen Y,et al.Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats[J].Biopharm Drug Dispos,2015:36(1):64-8.
[30] Li X,Chen C,Chen QQ,et al.An in vitro study on metabolic interaction between main active components of Salviae Miltiorrhizae Radix et Rhizoma and tacrolimus[J/OL].China Journal of Chinese Materia Medica(中国中药杂志).https://doi.org/10.19540/j.cnki.cjcmm.20200715.201.
[31] U.S.Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER).In Vitro Drug Interaction Studies-Cytochrome P450 Enzyme-and Transporter-Mediated Drug Interactions Guidance for Industry[EB/OL].(2020-01)[2020-09-09].https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs.
[32] Center for drug evaluation,NMPA of China.Safety information evaluation and management during drug clinical trials (trial)[EB/OL].(2020-07-01)[2020-09-09].http://www.cde.org.cn/news.do?method=largeInfo&id=938b81c153eaf85e.
[33] U.S.Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER).Clinical Drug Interaction Studies-Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry[EB/OL].(2020-06)[2020-09-09].https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs.
[34] ICH.E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER)[EB/OL].(2012-12-17)[2020-09-09].https://database.ich.org/sites/default/files/E2C_R2_Guideline.pdf.
[35] Lv J,Xie YM,Wang ZF,et al.Real world study on characteristics of Maixuekang capsules combined with traditional Chinese medicines in treating nephrotic syndrome[J],China journal of Chinese Materia Medica(中国中药杂志) ,2019,44(8):1668-1673.
[36] Mo K,Nong L,Cao W,et al.Research on adverse drug reaction monitoring based on Chinese hospital pharmacovigilance system[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2020,17(10):672-675.
[37] Shen CY,Wu TT,Liu W,et al.Post-marketing surveillance and evaluation of Chinese drugs in the new era[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2020,17(10):649-652,675.
[38] National Medical Products Administration of China.Guidelines for the collection and reporting of adverse drug reactions in individual cases[EB/OL].(2018-12-31)[2020-09-09].https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20181221172901438.html.
[39] Chen JJ,Qian PP,Cao K,et al.Comparison and analysis of causality assessment method in China and naranjo's method in the evaluation of adverse drug reactions[J].Chinese Pharmaceutical Affairs(中国药事),2020,34(8):988-992.
[40] Zhang XL,Shen XK,Huang YY.Clinical analysis of 130 cases of drug-induced liver injury in cancer patients[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2020,17(9):589-593.
[41] Yu Y.Adverse drug reaction knowledge integration and application research based on big data mining[D].Changchun:Jilin University(吉林大学) ,2016.
[42] Lyu TY,Kuang L,Chen MY.Analysis of 1073 cases of clinical use of reduning injection by Pareto chart and fishbone diagram[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2020,17(10):745-748.
[43] Wang XJ,Fang QY,Wei HJ.Pareto chart analysis on 96 cases of adverse reactions of Chinese patent medicine[J].China Pharmaceuticals(中国药业),2020,29(18):22-26.
[44] Zhu MJ,Zhang DD,Yang Y,et al.Efficacy and safety of oral snticoa--gulants in non-valvular atrial fibrillation therapy:a bayesian network meta-analysis[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2020,17(10):726-731.
[45] Wang M,Guo XJ,Ye XF,et al.Application of bayesian instrumental variable in active surveillance data of adverse drug reactions:a simulation study[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(3):139-143.
[46] Zang WX.Network technology was used to analyze the adverse reactions caused by cephalosporins combined with many western medicines[J].China New Telecommunications(中国新通信),2020,22(16):228.
[47] Li Q,Jin XY,Zhou X,et al.Analysis of differences between different research types in clinical safety evaluation of Xue bijing Injection[J/OL].China Journal of Chinese Materia Medica(中国中药杂志).https://doi.org/10.19540/j.cnki.cjcmm.20200715.201.
[48] Cheng JQ,Shi QP,Jiang XD,et al.Meta-analysis of incidence rates and influencing factors of adverse drug reactions related to salvianolate injection[J].ChineseJournal of Modern Applied Pharmacy(中国现代应用药学),2020,37(11):1355-1364.
[49] Wang M.Research and application of bayesian instrumental variable in active surveillance of adverse drug reaction[D].Xi’an:The Second Military Medical University,2019.

中药临床研究联合用药安全性评价的思考和建议

Thoughts and Suggestions on Safety Evaluation of Combined use of Traditional Chinese Medicine in Clinical Research

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李嘉昕, 刘慧敏, 钱文秀, 马宁, 宋丽丽, 李遇伯. 基于中药系统毒理学数据库的中药致肾毒性及药物规律研究[J]. 中国药物警戒, 2024, 21(2): 173-180.
[2]	张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189.
[3]	柏兆方, 湛小燕, 姚清, 陈思敏, 赵旭, 肖小河. 中药安全性评价理论创新与技术突破：病证毒理学[J]. 中国药物警戒, 2024, 21(1): 6-14.
[4]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[5]	方志娥, 李承贤, 柏兆方, 赵旭, 王伽伯, 肖小河. 马兜铃酸致肝癌的客观性研究与思考[J]. 中国药物警戒, 2024, 21(1): 20-24.
[6]	高源, 石伟, 肖小河, 柏兆方, 王伽伯. 特异质型药物性肝损伤体内评价模型研究进展[J]. 中国药物警戒, 2024, 21(1): 33-39.
[7]	李舒冉, 郭姗姗, 冀祖恩, 张薇, 崔晓兰. 新型冠状病毒感染后认知功能障碍的研究现状[J]. 中国药物警戒, 2024, 21(1): 59-64.
[8]	梅雨, 朱越, 张慧婷, 肖成荣, 高月, 马增春. 基于网络药理学和实验验证探讨中药复方CB001对低剂量辐射防护的作用机制[J]. 中国药物警戒, 2023, 20(8): 872-879.
[9]	严亦舒, 赵岩, 卢天公, 孙震晓. 大黄素-8-O-β-D-葡萄糖苷联合紫杉醇抑制人乳腺癌细胞活力及侵袭转移的研究[J]. 中国药物警戒, 2023, 20(7): 728-734.
[10]	王淑伟, 殷进军, 王冰, 宋彩萍, 杨福俊. 阿昔替尼片联合特瑞普利单抗治疗晚期肾癌致视网膜中央动脉阻塞1例分析[J]. 中国药物警戒, 2023, 20(7): 825-828.
[11]	丁子禾, 张彦琼, 林娜. 从脂质代谢途径探讨中药雷公藤“物-效/毒-靶”关联性的研究现状与展望[J]. 中国药物警戒, 2023, 20(5): 489-495.
[12]	罗琼, 李盟, 李光耀, 何彦春, 周祖山, 孙鑫, 刘成海. 635例类风湿性关节炎患者应用雷公藤制剂所致肝损伤的中医证候及联合用药特点[J]. 中国药物警戒, 2023, 20(5): 500-504.
[13]	聂黎行, 王馨平, 李静, 戴忠, 康帅, 马双成. 中药材（饮片）中马兜铃酸的含量分析及初步风险评估[J]. 中国药物警戒, 2023, 20(5): 553-559.
[14]	梁士兵, 余泽宇, 孔令垚, 晏利姣, 韩梅, 吴嘉瑞, 刘兆兰, 刘建平. 文献计量法在中药药物警戒领域中的应用价值及展望[J]. 中国药物警戒, 2023, 20(5): 591-594.
[15]	刘欢, 袁慧, 尹晶晶, 刘梦雅, 秦秀军, 李建国. 薏芽健脾凝胶幼龄大鼠的一般毒理学研究[J]. 中国药物警戒, 2023, 20(4): 416-422.